| ［1］ |
Boehncke WH, Schon MP. Psoriasis［J］. Lancet, 2015, 386（9997）:983⁃994. DOI: 10.1016/S0140⁃6736（14）61909⁃7.
|
| ［2］ |
Zanvit P, Konkel JE, Jiao X, et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis［J］. Nat Commun, 2015, 6: 8424. DOI: 10.1038/ncomms9424.
|
| ［3］ |
Baurecht H, Hotze M, Brand S, et al. Genome⁃wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms［J］. Am J Hum Genet, 2015, 96（1）: 104⁃120. DOI: 10.1016/j.ajhg.2014.12.004.
|
| ［4］ |
Quaranta M, Knapp B, Garzorz N, et al. Intraindividual genome analysis reveals a specific molecular signature of psoriasis and eczema［J］. Science Translational Medicine, 2014, 6（244）. DOI: ARTN 244ra9010.1126/scitranslmed.3008946.
|
| ［5］ |
Stuart PE, Nair RP, Tsoi LC, et al. Genome⁃wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture［J］. Am J Hum Genet, 2015, 97（6）: 816⁃836. DOI: 10.1016/j.ajhg.2015.10.019.
|
| ［6］ |
Yan S, Xu Z, Lou F, et al. NF⁃kappa B⁃induced microRNA⁃31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis［J］. Nat Commun, 2015, 6: 7652. DOI: Artn 765210.1038/Ncomms8652.
|
| ［7］ |
Man XY, Chen XB, Li W, et al. Analysis of epithelial⁃mesenchymal transition markers in psoriatic epidermal keratinocytes［J］. Open Biol, 2015, 5（8）. DOI: Artn 15003210.1098/Rsob.150032.
|
| ［8］ |
Hara⁃Chikuma M, Satooka H, Watanabe S, et al. Aquaporin⁃3⁃mediated hydrogen peroxide transport is required for NF⁃kappa B signalling in keratinocytes and development of psoriasis［J］. Nat Commun, 2015, 6: 7454. DOI: Artn 745410.1038/Ncomms8454.
|
| ［9］ |
Rizvi S, Chaudhari K, Syed BA. The psoriasis drugs market［J］. Nat Rev Drug Dis, 2015, 14（11）: 745⁃746. DOI: 10.1038/nrd4763.
|
| ［10］ |
Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate⁃to⁃severe chronic plaque psoriasis: a phase 3 randomised non⁃inferiority trial［J］. Lancet, 2015, 386（9993）: 552⁃561. DOI: 10.1016/S0140⁃6736（14）62113⁃9.
|
| ［11］ |
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis［J］. N Eng J Med, 2015, 373（14）: 1318⁃1328. DOI: 10.1056/Nejmoa1503824.
|
| ［12］ |
Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin⁃17A in patients with psoriatic arthritis［J］. N Eng J Med, 2015, 373（14）: 1329⁃1339. DOI: 10.1056/Nejmoa1412679.
|
| ［13］ |
Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis［J］. N Eng J Med, 2015, 373（2）: 136⁃144. DOI: 10.1056/Nejmoa1501646.
|
| ［14］ |
Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin⁃23［J］. Nature, 2015, 521（7551）: 222⁃226. DOI: 10.1038/nature14175.
|
| ［15］ |
Bachelez H. Interleukin⁃17 inhibition: a route to psoriasis clearance?［J］. Lancet, 2015, 386（9993）: 510⁃512. DOI: 10.1016/S0140⁃6736（15）60857⁃1.
|
| ［16］ |
Schukur L, Geering B, Charpin⁃El Hamri G, et al. Implantable synthetic cytokine converter cells with AND⁃gate logic treat experimental psoriasis［J］. Sci Tran Med, 2015, 7（318）: 318ra201. DOI: ARTN 318ra20110.1126/scitranslmed.aac4964.
|
| ［17］ |
Benedek T. Psoriasis and its specific vaccine therapy［J］. Acta Derm Venereol Suppl （Stockh）, 1955, 35（Suppl 33）: 1⁃20.
|
| ［18］ |
Benedek T. Specific vaccine therapy of psoriasis vulgaris, based on its etiology and pathogenesis［J］. Dermatol Wochenschr, 1955, 131（17）: 414⁃419.
|
| ［19］ |
Fry L, Baker BS, Powles AV. Psoriasis ⁃ a possible candidate for vaccination［J］. Clin Dev Immunol, 2006, 13（2⁃4）: 361⁃367. DOI: 10.1080/17402520600800861.
|
| ［20］ |
Baker BS, Owles AV, Fry L. A possible role for vaccination in the treatment of psoriasis?［J］. G Ital Dermatol Venereol, 2008, 143（2）: 105⁃117.
|
